Jatenzo FAERS Safety Signals: What the Post-Market Data Show

What Is Jatenzo and Why Does Post-Market Safety Surveillance Matter?

Jatenzo is the first oral testosterone replacement approved in the United States since methyltestosterone, a drug largely abandoned because of hepatotoxicity. Oral testosterone undecanoate avoids that hepatic first-pass problem by absorbing through intestinal lymphatics rather than the portal vein. That distinction matters for safety profiling, but it does not eliminate all risks.

Post-market surveillance fills in what clinical trials cannot. The key Swerdloff et al. Trial enrolled 166 hypogonadal men across 16 weeks, a sample too small and a period too short to detect rare or delayed adverse events with statistical confidence [1]. The FDA Adverse Event Reporting System (FAERS) collects spontaneous reports from patients, prescribers, and manufacturers after a drug reaches the market, producing signals that inform label updates, Risk Evaluation and Mitigation Strategies, and, in some cases, withdrawals.

How FAERS Signals Are Generated

A FAERS signal is not a confirmed causal finding. It is a statistical association. The FDA uses the Empirical Bayes Geometric Mean (EBGM) and the proportional reporting ratio (PRR) to identify drug-event pairs reported more often than background noise would predict. A PRR above 2.0 with at least three reports and a chi-squared statistic above 4.0 meets the standard threshold for a candidate signal worth investigating [2].

Sponsors are legally required under 21 CFR 314.81 to submit quarterly safety reports for the first three years post-approval, then annual reports thereafter, incorporating FAERS data and any new clinical evidence [3]. Tolmar's post-market obligations for Jatenzo fall under this framework.

The Lymphatic Absorption Mechanism and Its Safety Implications

Because testosterone undecanoate is absorbed via chylomicrons into intestinal lymphatics, co-administration with a fatty meal is required for consistent bioavailability. The FDA label specifies that Jatenzo must be taken with food containing at least 20 grams of fat [4]. Skipping a fatty meal drops peak testosterone (Cmax) by approximately 44%, according to pharmacokinetic data submitted in NDA 210528 [4]. Erratic absorption also contributes to variable hematocrit responses, which is relevant to the erythrocytosis signal discussed later.

FDA Approval History and Label Evolution

The FDA approved Jatenzo on March 27, 2019, under NDA 210528, for adult males with hypogonadism caused by conditions affecting the testes, pituitary, or hypothalamus [4]. The approval was not extended to age-related hypogonadism without an identified organic cause, mirroring the FDA's longstanding position on testosterone labeling [5].

The 2019 Boxed Warning

At approval, the FDA required a boxed warning. The label states: "Increases in blood pressure can occur with JATENZO and may increase the risk of major adverse cardiovascular events (MACE) including non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death. Before initiating JATENZO, consider the patient's baseline cardiovascular risk" [4]. This language is unusually specific for an approval-day boxed warning, reflecting concerns raised during the FDA's internal review of the Swerdloff et al. Data.

In the key trial, 21.4% of participants required antihypertensive treatment initiation or dose escalation during the 16-week study period [1]. Systolic blood pressure increased by a mean of 3.5 mmHg and diastolic blood pressure by a mean of 2.0 mmHg from baseline [1]. Those numbers look modest in isolation. Across a population of men with pre-existing cardiovascular risk factors, a 3- to 4-mmHg sustained systolic rise translates to a meaningfully higher absolute risk of stroke, as meta-analyses of antihypertensive trials have long established [6].

Label Updates Since 2019

The Prescribing Information has been updated since original approval to clarify dose titration instructions and to add language about drug interactions with insulin and oral anticoagulants. Testosterone can increase sensitivity to warfarin; the label now recommends checking the INR more frequently when Jatenzo is initiated or discontinued [4]. Prescribers should always consult the current label via Drugs@FDA rather than relying on older printed copies, because label text is a living document that changes as post-market data accumulate [4].

FAERS Safety Signals for Jatenzo: Current Findings

FAERS data for oral testosterone undecanoate, queried through the FDA's publicly accessible OpenFDA API, reveal several recurring event categories. Because Jatenzo is a branded product with a unique NDA number, its FAERS reports can be separated from intramuscular or transdermal testosterone formulations with reasonable precision.

Cardiovascular and Blood Pressure Events

Hypertension and hypertensive crisis are the most numerically prominent adverse event terms in Jatenzo FAERS submissions. This signal is biologically coherent: testosterone stimulates erythropoiesis, raises hemoglobin and hematocrit, increases blood viscosity, and may activate the renin-angiotensin-aldosterone system [7]. Observational data from the FDA Sentinel System, which queries insurance claims across more than 100 million covered lives, have been used to examine testosterone-associated MACE risk across formulations, though Jatenzo's relatively small market share limits Sentinel's formulation-specific statistical power [8].

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in 788 men 65 years or older, are relevant context. Cardiovascular findings in TTrials showed a non-significant numerical trend toward more coronary artery non-calcified plaque volume in the testosterone arm over 12 months [9]. That trial used transdermal testosterone, not oral undecanoate, so direct extrapolation to Jatenzo requires caution. The signal is nonetheless consistent with the biological plausibility of androgen-mediated atherogenesis in older men.

Erythrocytosis and Polycythemia

Erythrocytosis (hematocrit above 54%) appears consistently in both the label and FAERS reports for Jatenzo. Testosterone stimulates erythropoietin production, and oral undecanoate's variable absorption creates concentration peaks that may intermittently drive supraphysiologic testosterone levels, amplifying the erythropoietic effect [10]. The FDA label recommends checking hematocrit at baseline, at 3 to 6 months, and then annually [4]. If hematocrit exceeds 54%, the label advises holding the dose until hematocrit falls to a safe level, then restarting at a lower dose or discontinuing [4].

Erythrocytosis raises whole-blood viscosity, which is one mechanism proposed for testosterone's association with venous thromboembolism (VTE). A large nested case-control study published in BMJ found that testosterone use was associated with an approximately 2-fold increased VTE risk in the first 6 months of therapy (OR 1.95; 95% CI 1.46 to 2.61) [11]. The study was not specific to oral undecanoate, but the hematological pathway applies across formulations.

Mood, Psychiatric, and Behavioral Reports

FAERS includes a meaningful cluster of mood-related reports for Jatenzo: irritability, aggression, and mood swings. These are consistent with known pharmacology of supraphysiologic androgen exposure, and they appear in the label under Warnings and Precautions [4]. Reports of depression also appear, possibly reflecting the nadir of testosterone levels between doses in men who absorb the drug erratically.

The clinical significance of individual psychiatric FAERS reports is hard to quantify without clinical context. Confounders are substantial: men seeking testosterone therapy often have co-existing mood disorders, sleep apnea, or metabolic syndrome. When a patient reports worsening mood after starting Jatenzo, checking a serum testosterone level at both peak (approximately 6 hours post-dose) and trough (before the next dose) is a reasonable first step [4].

Hepatic Events

One concern raised about oral testosterone historically is hepatotoxicity, given the legacy of 17-alpha-alkylated androgens like methyltestosterone. Jatenzo is not 17-alpha-alkylated. The lymphatic absorption route bypasses first-pass hepatic metabolism almost entirely, and hepatotoxicity is not listed as a warning in the current Jatenzo label [4]. FAERS does contain isolated liver-related reports for testosterone products broadly, but the signal rate for oral undecanoate specifically does not appear elevated compared with background reporting for any oral medication [2].

Interpreting FAERS Data: Methodological Cautions

FAERS has well-documented limitations that every reader of spontaneous-reporting summaries must understand. Reports are submitted voluntarily by patients and prescribers, creating substantial underreporting for expected or mild events. The database does not capture denominator data, meaning you cannot calculate incidence rates directly from FAERS counts alone. Duplicate reports, missing data fields, and coding inconsistencies further complicate signal interpretation [2].

Signal Versus Causation

A FAERS signal means only that a drug-event pair is reported more often than statistical noise predicts. It does not confirm the drug caused the event. For testosterone specifically, the underlying condition being treated (hypogonadism) is itself associated with metabolic syndrome, cardiovascular disease, and mood disturbance. Men who seek testosterone therapy may have higher baseline cardiovascular risk than the general population, inflating apparent signal strength [12].

Comparison With Other Testosterone Formulations

Interpreting Jatenzo's FAERS profile in isolation is misleading without context. Testosterone cypionate and enanthate have decades of post-market reports and much higher prescription volumes. Blood pressure and erythrocytosis signals appear across all testosterone formulations. What distinguishes Jatenzo's profile is the boxed warning specificity around blood pressure and the dose-with-food requirement that creates absorption variability not seen with intramuscular or transdermal routes [4].

Clinical Monitoring Protocol Based on Label and FAERS Signals

The FDA-approved label, combined with the FAERS signal pattern, supports a specific monitoring approach that prescribers should document in the patient record.

Before Starting Jatenzo

Blood pressure should be measured and recorded. Men with uncontrolled hypertension (systolic above 160 mmHg or diastolic above 100 mmHg) should not start Jatenzo until blood pressure is controlled [4]. A baseline hematocrit and hemoglobin, serum testosterone (morning, fasting), PSA, and lipid panel are all appropriate at initiation [13]. The Endocrine Society Clinical Practice Guideline on male hypogonadism supports this baseline workup [13].

The Endocrine Society guideline states: "We suggest measuring hemoglobin and hematocrit before starting testosterone therapy, at 3 to 6 months, and then annually" [13]. This language was written for testosterone therapy broadly, but it aligns precisely with what Jatenzo's label requires.

During the First Three Months

Blood pressure should be rechecked at the 3-month visit. The label specifies this interval explicitly [4]. Serum testosterone drawn approximately 6 hours after the morning dose guides dose titration. The starting dose is 237 mg (one 158 mg capsule plus one 79 mg capsule, or as directed) twice daily, and the label permits titration up to 396 mg twice daily or down to 158 mg twice daily based on the Cavg [4].

Hematocrit rechecked at 3 months catches early erythrocytosis before it becomes symptomatic. A value above 54% requires dose interruption per label guidance [4].

Ongoing Monitoring

After the first 3 months, monitoring frequency follows clinical judgment. Annual hematocrit, blood pressure at each visit, and periodic PSA in men over 40 years represent a defensible standard of care [13]. The FDA has not required a REMS program for Jatenzo, in contrast to topical testosterone products that carry a pediatric transference warning [5].

What Prescribers Should Document

Documentation protects the patient and the prescriber. Every Jatenzo-related office note should record the indication (organic hypogonadism with serum testosterone below 300 ng/dL on two morning measurements, per Endocrine Society standards) [13], the blood pressure value at that visit, the current dose, and any adverse symptoms reported by the patient. If a patient reports worsening hypertension and that is attributed to Jatenzo, the prescriber should submit a MedWatch report to FAERS. Voluntary reporting by clinicians directly strengthens post-market surveillance and improves the quality of the signals that protect future patients [2].

The FDA MedWatch portal accepts reports at fda.gov/safety/medwatch [14]. Reporting takes approximately 10 minutes and does not require proof of causation. Suspicion alone is sufficient and appropriate.

Jatenzo in the Broader Testosterone Safety Debate

The FDA issued a safety communication in 2015 requiring all testosterone products to carry labeling about cardiovascular risk and advising that prescribers discuss this risk with patients [5]. That communication followed a series of observational studies that produced conflicting results. The TRAVERSE trial, a randomized cardiovascular outcomes trial in 5,204 men with hypogonadism and elevated cardiovascular risk, was published in the New England Journal of Medicine in 2023 and found that transdermal testosterone was non-inferior to placebo for MACE (HR 0.96; 95% CI 0.78 to 1.17) over a median 33 months [15]. Jatenzo was not the study drug, but TRAVERSE is now the most important piece of evidence informing the class-wide cardiovascular debate, and clinicians discussing Jatenzo's cardiovascular risk profile should be familiar with its findings.

TRAVERSE did find higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone arm compared with placebo, each reaching statistical significance [15]. These signals mirror categories visible in FAERS data for testosterone products broadly, including Jatenzo.